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THE majority of sera from naso-
pharyngeal carcinoma (NPC) patients
studied to date was shown to have a titre
of IgA antibodies to the Epstein-Barr
viral capsid antigen (VCA) of 1/10, while
the same reactivity was seldom detectable
in the seraofcontrols consisting ofpatients
with other cancers and healthy subjects
(Henle and Henle, 1976; Ho et al., 1976
and in preparation). In all these sera, the
detection of IgA reactivity to VCA was
concomitant with high titres of IgG anti-
bodies to VCA. This led to the conclusion
that both serum reactivities might reflect
the intensity of systemic stimulation by
EBV-specific antigens (Ho et al., 1976).
However, these findings did not exclude a
concurrent production of local antibodies.
Indeed, in view of the fact that discharge
from NPC readily finds its way to the oral
cavity and the saliva, and the close
association known to exist between the
neoplastic disease and EBV (Klein, 1973;
Ho, 1975; de-The, et al., 1975), production
of local antibodies to VCA may well be
anticipated. We therefore tested the
saliva obtained from NPC patients and
controls for the presence ofIgA antibodies
to EBV VCA.
Parallel specimens of saliva and sera
were obtained from 30 histologically
confirmed NPC patients before treatment
(4 with Stage I disease, 2 Stage II, 7 Stage
III, 14 Stage IVand 5 Stage V), 20 patients
with other cancers (OC) (10with carcinoma
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of bronchus, 1 of uterine corpus, 2 of
bladder, 1 of stomach, 1 of kidney, 3 of
cervix, 1 of ovary and 1 of testis) and 10
healthy subjects (HS) selected from the
laboratory personnel.
Saliva was concentrated 20-fold
(Amicon, U.S.A.) and sera, diluted 1/10
were tested by the indirect immuno-
fluorescent technique for the presence of
IgA reactivity to VCA, using acetone-fixed
Jijoye cell smears as described previously
(Ho et al., 1976), except that parallel
smears were counterstained with fluore-
scein-conjugated anti-human IgA specific
for alpha chains (FITC-anti-cx) and anti-
human secretory piece of IgA (FITC-anti-
SP) (Dako, Copenhagen, Denmark). The
smears were examined with the Tiyoda
FA200B fluorescent microscope. Only
smears showing over 1% of definite
fluorescent cells among at least 500 cells
counted were considered as positive.
Double-diffusion analysis was per-
formed according to the method described
by Thompson et al., (1969) using Dako
monospecific rabbit anti-human alpha
chains and secretory piece (anti-cc, and
anti-SP).
Using the FITC anti-ac serum, IgA
reactivity to VCA was detected in all the
30 sera and 24 saliva specimens from the
NPC patients, while none of the controls
displayed this reactivity in either their
sera or saliva (Table I). Parallel counter-
staining with FITC-anti-SP serumIgG ANTIBODIES TO EBV IN SALIVA 889
TABLE I.-Frequencies of Detection ofIgA antibodies to VCA by Immunoftuorescence
Saliva Serum
Cases Number FITC-anti-oi FITC-anti-SP FITC-anti-oc FITC-anti-SP
NPC 30 24 1 30 0
OC 20 0 0 0 0
HS 10 0 0 0 0
TABLE II.-Detection ofImmunoglobulins in Saliva and Sera by Double Immunodiffusion
Serum Saliva
Cases Number IgG IgA IgM IgG IgA IgM
anti-o anti-SP anti-cx anti-SP
INPC 30 30 30 0 30 27 30 30 0
OC 20 20 20 0 20 19 20 19 0
HS 10 10 10 10 10 9 10 10 0
revealed IgA reactivity to VCA in none of
the sera, and in only one saliva specimen
from NPC patients (Table I). In this
particular instance, both methods of
counterstaining revealed between 2 and
4% VCA-positive cells of similar intensity
of immunofluorescence.
The sera and saliva specimens were
tested for the presence of immuno-
globulins by radial immunodiffusion. It
is of interest that serum IgA was only
detectable with the anti-a serum, while
saliva IgA formed immune precipitate
with either the anti-oc or anti-SP sera. IgG
was detected in the salivas of 27 NPC and
19 OC patients and 9 HS but none of the
saliva tested contained detectable
quantities of IgM (Table II).
The detection ofIgA reactivity to VCA
in the sera of all the NPC patients, and
not in the sera ofthe controls, is in general
agreement with our earlier observation
(Ho, 1976; and in preparation) and those
of Henle and Henle (1976). The discri-
minatory capability of these IgA anti-
bodies in the VCA test for NPC makes it
a valuable diagnostic aid for the detection
of the disease.
The concomitant detection of IgA
antibodies to VCA in the sera and saliva
of NPC patients is anticipated in view of
the close association between EBV and
NPC, and the ready contamination by the
discharge from the tumour in the naso-
pharynx (Klein, 1973; Ho, 1975). Indeed
IgA reactivity to VCA was detected using
FITC-anti-a in 24/30 salivas from the NPC
patients, and this reactivity was not
detectable in the saliva from the control
subjects. IgA antibodies to VCA were
also detected using the FITC-anti-SP
serum in 1 saliva specimen from an NPC
patient. In this particular instance, it is
clear that both methods ofcounterstaining
are of comparable sensitivity, giving rise
to similar numbers of positive cells which
displayed similar intensity of immuno-
fluorescence. This indicated that the IgA
antibodies to VCA in this instance may
exist in the dimeric form withthe attached
secretory piece as other IgA molecules
produced locally in the saliva (Tomasi,
1970). The IgA antibodies to VCA in the
saliva specimens from the other NPC
patients, however, do not appear to
contain the secretory piece. This finding
indicates that the secretory piece might
have been dissociated from the IgA
molecule prior to testing. Alternatively,
it is also possible that the IgA antibodies
to VCA in the saliva from the majority of
NPC patients might have a systemic
originandthey,therefore,lackthesecretory
piece. Further investigations are, how-
ever, necessary to test these possibilities.
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